Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | BRD2 | P25440 | 5/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12307489 | 0.89 | KMT2A (0.39) | ALDH1A1NPC1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL12307398 | 0.88 | GCK (0.40) | ALDH1A1NPC1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL12307522 | 0.87 | ALDH1A1 (0.38) | ALDH1A1TP53BRD4BRD2BRD3 | |
| SCHEMBL12307566 | 0.86 | GRM5 (0.35) | SMN1; SMN2 | |
| SCHEMBL12307581 | 0.86 | BRD4 (0.38) | ALDH1A1BRD4BRD2SMN1; SMN2KMT2A | |
| SCHEMBL12307539 | 0.86 | MEN1 (0.42) | ALDH1A1TP53MALT1NPC1MAPT | |
| SCHEMBL12307510 | 0.85 | AOC3 (0.40) | ALDH1A1MAPTRAB9AKMT2A | |
| SCHEMBL12307589 | 0.84 | F10 (0.36) | ALDH1A1BRD4BRD2BRD3SMN1; SMN2 | |
| SCHEMBL12307596 | 0.82 | MAPK13 (0.38) | NPC1MAPTSMN1; SMN2RAB9AKMT2A | |
| SCHEMBL12307609 | 0.82 | TTR (0.39) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R5, PIK3R4, PIK3R1 | ALDH1A1 3559/4885TP53 342/4885BRD4 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.